(24/7 MARKET NEWS) – Verona Pharma plc (Nasdaq: VRNA) opened today’s trading session at $22.01 and is now trading at $24.6587, up $2.7737 (+22.31%), on 300 thousand shares traded.
24/7 market news first covered Verona Pharma after it announced, last week, that its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine successfully met its primary and key secondary endpoints demonstrating significant improvements in lung function, symptoms and quality of life measures. Additionally, ensifentrine substantially reduced the rate and risk of COPD exacerbations. Ensifentrine was well tolerated over 24 and 48 weeks.
Verona Pharma was trading at $16.50 that it could “now try to target 2018 trading levels.” Verona Pharma now has all time highs in its sights.
Its 52-week range was $3.4078 to $24.6587.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.